Zacks Research Downgrades Kiniksa Pharmaceuticals International (NASDAQ:KNSA) to Strong Sell

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the stock. TD Cowen began coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a “buy” rating and a $60.00 target price for the company. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. The Goldman Sachs Group increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Wedbush increased their price target on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a report on Tuesday. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $52.33.

Kiniksa Pharmaceuticals International Stock Up 2.5%

KNSA opened at $39.56 on Tuesday. The firm has a market capitalization of $3.00 billion, a P/E ratio of 87.91 and a beta of 0.04. The stock has a fifty day moving average of $41.34 and a 200-day moving average of $36.60. Kiniksa Pharmaceuticals International has a 12-month low of $18.12 and a 12-month high of $44.42.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). The business had revenue of $180.86 million during the quarter, compared to analysts’ expectations of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm’s revenue was up 61.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.18) earnings per share. On average, analysts expect that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider John F. Paolini sold 82,542 shares of the business’s stock in a transaction dated Friday, October 31st. The stock was sold at an average price of $37.14, for a total transaction of $3,065,609.88. Following the transaction, the insider directly owned 61,324 shares in the company, valued at $2,277,573.36. The trade was a 57.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Sanj K. Patel sold 97,390 shares of the company’s stock in a transaction that occurred on Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total value of $3,781,653.70. Following the completion of the transaction, the chief executive officer directly owned 111,794 shares of the company’s stock, valued at approximately $4,340,961.02. This trade represents a 46.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 510,689 shares of company stock valued at $20,009,290 in the last quarter. 53.48% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC increased its holdings in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the period. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $31,000. USA Financial Formulas acquired a new position in Kiniksa Pharmaceuticals International in the third quarter worth about $32,000. Quantbot Technologies LP acquired a new position in Kiniksa Pharmaceuticals International in the second quarter worth about $43,000. Finally, Quarry LP bought a new position in Kiniksa Pharmaceuticals International during the third quarter worth about $44,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.